Home
Research
Submit Article
News
Sectors
Advertise
Premium
i On The Market - Daily Newsletter
Every trading day, be ready to attack the market instead of reacting to the market.
You will know where the key technical resistance and support levels are and what the market is likely to do next. iStock will arm you with a target list of stocks to buy and sell - right now - based on our exclusive, proprietary trading models.
Two Week FREE Trial
About Us
About Us
Editorial Staff
Terms and Conditions
Privacy Policy
Contact Us
iStock Rating
A
Details...
Enter Symbol
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX)
Sector: Medical
Current Price :
$7.66
52 Week Low
$1.71
52 Week High
$9.08
Company
Overview
Research Notes
Company Profile
Competitors
Community
Stock Sentiment
Whisper Estimates
Enter Estimates
Analysis
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Press Releases
Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals
Keryx Biopharmaceuticals, Inc. Announces Zerenex(TM) Phase 3 Data Presented at the 2013 World Congress of Nephrology
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results
Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2013 Financial Results
Morning Research on Sanofi, Keryx Biopharma, VIVUS, and Array BioPharma
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- KERX
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Keryx Biopharmaceuticals, Inc. to Contact the Firm -- KERX
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position
Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
Programs by the FDA Designed to Speed Up Approval Process for Critical Drugs a Key Factor in Biotech's Industry Success
SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Keryx Biopharmaceuticals, Inc., and Certain Officers -- KERX
Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
High Profile HealthCare Companies: Leading Pharma Company Secures New Patents
Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors of Upcoming Deadlines in Shareholder Litigation Involving magicJack VocalTec LTD., Tellabs, Inc. and Keryx Biopharmaceuticals
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Harwood Feffer LLP Announces Investigation of Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
Levi & Korsinsky Notifies Investors With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position
Keryx Biopharmaceuticals Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Levi & Korsinsky Notifies Investors With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position -- KERX
Brower Piven Encourages Investors Who Have Losses in Excess of $150,000 From Investment in Keryx Biopharmaceuticals, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the April 2, 2013 Lead Plaintiff Deadline
High Profile Stock News Alert: Leading Pharma Company Gets New Patents Approved
Bronstein, Gewirtz & Grossman, LLC Announces That A Class Action Has Been Filed Against Kerx Biopharmaceuticals, Inc.
Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX)
Free Research Report on Keryx Biopharmaceuticals, Inc., iShares, Inc., ConAgra Foods, Inc. and Aon Plc
Faruqi & Faruqi, LLP Files Class Action Lawsuit Against Keryx Biopharmaceuticals, Inc. -- KERX
Number of FDA Drug Approvals Reach a 15-Year High in 2012
Pharmaceutical Company Achieves Positive In-Vitro Testing Results Diabetes Drug
Foresite Capital Management Closes $100 Million Growth Capital Fund to Finance Late-Stage Healthcare Companies
Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
Top Stock Movers: Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), Zynga Inc. (NASDAQ: ZNGA), Glu Mobile, Inc. (NASDAQ: GLUU), Radioshack Corporation (NYSE: RSH)
Keryx Biopharmaceuticals Announces Zerenex(tm) (ferric citrate) Meets Primary and All Key Secondary Endpoints in Phase 3 Long-Term Study as a Treatment for Hyperphosphatemia in End-Stage Renal Disease Patients on Dialysis
Keryx Biopharmaceuticals to Hold Conference Call Tomorrow at 8:00 AM ET to Discuss Top-Line Results from Zerenex(tm) Phase 3 Long-Term Study
Our Pros Knew KERX, DANG, VHC and ES Would Be Top Gainers on Monday
Keryx Biopharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
Keryx Biopharmaceuticals Announces Filing of New Drug Application for Marketing Approval of Ferric Citrate (Zerenex(tm)) in Japan by Partner, Japan Tobacco Inc.
Keryx Biopharmaceuticals Announces that Congress Delays Implementation of Oral-Only ESRD-Related Drugs, Including Phosphate Binders, in the Bundled ESRD Prospective Payment System by Two-Years, until January 2016
Keryx Biopharmaceuticals to Present at The Oppenheimer & Co. Inc. 23rd Annual Healthcare Conference
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Keryx Biopharmaceuticals Initiates Phase 2 Study of Zerenex(tm) (ferric citrate) for the Treatment of Patients with Non-Dialysis Dependent Chronic Kidney Disease
Biotech Industry Look to Benefit From New Act Designed to Promote R&D Joint Ventures
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Keryx Biopharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
Favorable Legislation Introduced in 2012 Helps Accelerate Biotech Industry Growth in 2012
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
Four Small Biotechs You Should Know: (NASDAQ: KERX), (NASDAQ: GERN), (NASDAQ: CTIC), (OTCBB: ONCS)
Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
Merger and Acquisition Activity and Speculation Growing as Large Pharmaceuticals Look to Replace Revenues From Lost Patents
Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
Keryx Biopharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex(tm) (ferric citrate) at the 49th ERA-EDTA Congress
Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference
Keryx Biopharmaceuticals Announces Upcoming Poster Presentations of Zerenex(tm) (ferric citrate) at National Kidney Foundation (NKF) 2012 Spring Clinical Meetings
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
Keryx Biopharmaceuticals Announces Reversion of KRX-0401 (Perifosine) License Rights to Aeterna Zentaris
Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex(tm)) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
Keryx Biopharmaceuticals Announces Top-Line Data from the Perifosine (KRX-0401) X-PECT Phase 3 Clinical Trial
Cell Therapeutics and Keryx Biopharmaceuticals Hope for Help From the TREAT Act
4 Active Stocks on Traders Radar Screens for 03/05/12: WDKA, SIRI, KERX, BP
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results
Keryx Biopharmaceuticals to Present at Citi's 2012 Global Health Care Conference
Keryx Biopharmaceuticals to Present at 14th Annual BIO CEO and Investor Conference
A Change in Tides - Featured Research on Keryx Biopharmaceuticals and AEterna Zentaris Inc. (USA)
Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkin's Lymphoma Presented at ASH Meeting
Keryx Biopharmaceuticals Announces Upcoming Presentations on KRX-0401 (Perifosine) at 53rd Annual Meeting of American Society of Hematology
Keryx Biopharmaceuticals Announces Highlights from Zerenex(tm) (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
Europe Situation Forecasts Change -- Report Highlights NetApp Inc. and Keryx Biopharmaceuticals
Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex(tm) (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
Global Situation & Resulting Influences - Research Report on Keryx Biopharmaceuticals and AEterna Zentaris Inc. (USA)
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex(tm) (Ferric Citrate) Phase 3 Long-Term Study
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Keryx Biopharmaceuticals Announces Completion of Interim Analysis by Data Safety Monitoring Board for the Phase 3 Study of KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
Keryx Biopharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference
Rodman & Renshaw Acts as a Co-Manager to Keryx Biopharmaceuticals, Inc. in Common Stock Offering
Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
Keryx Biopharmaceuticals Receives Positive Scientific Advice from the European Medicines Agency for Zerenex(tm) in Hyperphosphatemia
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex(tm) Short-Term Phase 3 Study
Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex(TM)) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
Keryx Biopharmaceuticals Announces Results on KRX-0401 (Perifosine) at American Association for Cancer Research Annual Meeting
Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex(tm) Short-Term Phase 3 Data at the Upcoming National Kidney Foundation's 2011 Spring Clinical Meetings
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##